Health technology company Fibronostics, which specialises in non-invasive diagnostics for metabolic and liver diseases,, announced on Monday that it has completed the acquisition of Stone Clinical Laboratories LLC, a US-based provider of advanced laboratory services.

This acquisition strengthens Fibronostics' research and development position and reinforces its commitment to innovation in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD).

According to Fibronostics, the combined organisation is well-positioned to partner with biopharma innovators, healthcare systems, and payers to expedite early detection and improve outcomes for patients.